Buyback yield (TTM)
0.39%
Shareholder yield (TTM)
3.45%
5Y share count change
6.0%
Buyback spend (TTM)
$1.51B
Cumulative buybacks
$36.72B
Key takeaways
- AbbVie (ABBV) repurchased about $1.51B of stock over the trailing twelve months.
- Diluted share count is up 6.0% over the last ~5 fiscal years — equity issuance and stock-based compensation are outpacing repurchases.
- TTM buyback ÷ stock-based-comp ratio of 1.52× — repurchases more than cover SBC dilution.
- Cash buyback spend has compounded at +0.0% per year over the latest 5-year window.
- TTM repurchases used about 17% of free cash flow remaining after dividends.
Dividend & buyback yield over time for AbbVie (ABBV)
Stacked annual yields — buyback yield (TTM cash repurchases ÷ market cap) plus dividend yield from the same fiscal-year-end key-metrics period — show how total cash return per dollar of equity has evolved.
Diluted vs basic shares (annual) for AbbVie (ABBV)
Diluted weighted-average shares are the EPS denominator — a falling count means buybacks are outpacing SBC dilution.
Year-over-year change in diluted shares for AbbVie (ABBV)
Green is fewer shares vs the prior fiscal year (net repurchase); red is growth (dilution). The earliest year shown has no prior year to compare.
Cash buyback spend over time for AbbVie (ABBV)
Latest: $980.00M
Overview
In 2025, AbbVie (ABBV) buyback spend totalled $980.00M – plunged 42.6% year-over-year.
AbbVie buyback spend has grown on net over the period, with a +0.0% compound annual growth rate over 2020–2025 (5 years).
Between 2018 and 2025, AbbVie buyback spend plunged 91.8%, falling from $12.01B to $980.00M.
$12.01B stands as the all-time-high annual buyback spend, posted in 2018, against a low of $0.00 during 2009.
AbbVie Buyback Spend 2025: $980.00M
AbbVie posted buyback spend of $980.00M in 2025, plunged 42.6% below 2024.
AbbVie Buyback Spend 2024: $1.71B
In 2024, AbbVie reported buyback spend of $1.71B, declined 13.4% below 2023.
AbbVie Buyback Spend 2023: $1.97B
AbbVie buyback spend in 2023 was $1.97B, surged 32.6% from 2022.
AbbVie Buyback Spend 2022: $1.49B
2022's buyback spend for AbbVie came in at $1.49B, surged 59.2% from 2021.
AbbVie Buyback Spend 2021: $934.00M
AbbVie buyback spend in 2021 was $934.00M.
See more financial history for AbbVie (ABBV).
Buyback, SBC & dilution history
Buyback spend, SBC, net dilution effect, and share count.
| 2025 | $980.00M | $955.00M | $25.00M | 0.24% | 1.77B | +0.1% | |
| 2024 | $1.71B | $911.00M | $797.00M | 0.54% | 1.77B | 0.0% | |
| 2023 | $1.97B | $747.00M | $1.23B | 0.72% | 1.77B | -0.3% | |
| 2022 | $1.49B | $671.00M | $816.00M | 0.52% | 1.78B | +0.1% | |
| 2021 | $934.00M | $692.00M | $242.00M | 0.39% | 1.78B | +6.2% | |
| 2020 | $978.00M | $753.00M | $225.00M | 0.52% | 1.67B | +12.7% | |
| 2019 | $629.00M | $430.00M | $199.00M | 0.48% | 1.48B | -4.0% | |
| 2018 | $12.01B | $421.00M | $11.59B | 8.80% | 1.55B | -3.6% | |
| 2017 | $1.41B | $365.00M | $1.04B | 0.92% | 1.60B | -1.7% | |
| 2016 | $6.03B | $353.00M | $5.68B | 6.05% | 1.63B | -0.4% | |
| 2015 | $7.59B | $282.00M | $7.30B | 7.95% | 1.64B | +1.7% | |
| 2014 | $665.00M | $241.00M | $424.00M | 0.64% | 1.61B | +0.4% | |
| 2013 | $320.00M | $212.00M | $108.00M | 0.38% | 1.60B | +1.7% | |
| 2012 | $0.00 | $187.00M | −$187.00M | — | 1.58B | -3.0% | |
| 2011 | $0.00 | $162.98M | −$162.98M | — | 1.63B | 0.0% | |
| 2010 | $0.00 | $167.00M | −$167.00M | — | 1.63B | 0.0% | |
| 2009 | $0.00 | $156.72M | −$156.72M | — | 1.63B | — |
- 2025$980.00M
- 2024$1.71B
- 2023$1.97B
- 2022$1.49B
- 2021$934.00M
- 2020$978.00M
- 2019$629.00M
- 2018$12.01B
- 2017$1.41B
- 2016$6.03B
- 2015$7.59B
- 2014$665.00M
- 2013$320.00M
- 2012$0.00
- 2011$0.00
- 2010$0.00
- 2009$0.00
Buybacks vs stock-based compensation for AbbVie (ABBV)
Annual cash repurchases set against stock-based compensation. Coverage above 1× means buybacks fully offset the equity dilution from SBC. TTM coverage: 1.52×.
Buybacks vs dividends (share of cash returned) for AbbVie (ABBV)
How AbbVie splits cash returned to shareholders between dividends and buybacks.
Sector peers by buyback spend
Companies in the same sector as AbbVie, ranked by their latest buyback spend.
| $5.95B | |
| $5.54B | |
| $5.08B | |
| $4.11B | |
| $3.00B | |
| $216.35M | |
| $0.00 | |
| $0.00 |
- $5.95B
- $5.54B
- $5.08B
- $4.11B
- $216.35M
- $0.00
- $0.00
Buyback capacity (TTM)
Free cash flow minus dividends paid versus actual TTM repurchases — the headroom bar shows how much of post-dividend FCF is still being deployed elsewhere.
Headroom $9.05B (TTM FCF − TTM dividends, clamped at zero).
Frequently asked questions
Data & methodology
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation